The DOI matches its Crossref record; 38 of the 38 references it cites were found in a registry or an index.
Critical Role of O-Linked β-N-Acetylglucosamine Transferase in Prostate Cancer Invasion, Angiogenesis, and Metastasis
Open accessAbstract
Cancer cells universally increase glucose and glutamine consumption, leading to the altered metabolic state known as the Warburg effect; one metabolic pathway, highly dependent on glucose and glutamine, is the hexosamine biosynthetic pathway. Increased flux through the hexosamine biosynthetic pathway leads to increases in the post-translational addition of O-linked β-N-acetylglucosamine (O-GlcNAc) to various nuclear and cytosolic proteins. A number of these target proteins are implicated in cancer, and recently, O-GlcNAcylation was shown to play a role in breast cancer; however, O-GlcNAcylation in other cancers remains poorly defined. Here, we show that O-GlcNAc transferase (OGT) is overexpressed in prostate cancer compared with normal prostate epithelium and that OGT protein and O-GlcNAc levels are elevated in prostate carcinoma cell lines. Reducing O-GlcNAcylation in PC3-ML cells was associated with reduced expression of matrix metalloproteinase (MMP)-2, MMP-9, and VEGF, resulting in inhibition of invasion and angiogenesis. OGT-mediated regulation of invasion and angiogenesis was dependent upon regulation of the oncogenic transcription factor FoxM1, a key regulator of invasion and angiogenesis, as reducing OGT expression led to increased FoxM1 protein degradation. Conversely, overexpression of a degradation-resistant FoxM1 mutant abrogated OGT RNAi-mediated effects on invasion, MMP levels, angiogenesis, and VEGF expression. Using a mouse model of metastasis, we found that reduction of OGT expression blocked bone metastasis. Altogether, these data suggest that as prostate cancer cells alter glucose and glutamine levels, O-GlcNAc modifications and OGT levels become elevated and are required for regulation of malignant properties, implicating OGT as a novel therapeutic target in the treatment of cancer.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
2 retracted
Wang, Z., Banerjee, S., Kong, D., Li, Y., & Sarkar, F. H. (2007) · Cancer Research · doi:10.1158/0008-5472.can-07-1265 · Cited by 245
RetractedAhmad, A., Wang, Z. P., Kong, D., Ali, S. S., Li, Y., Banerjee, S., Raza, A., & Sarkar, F. H. (2009) · Breast Cancer Research and Treatment · doi:10.1007/s10549-009-0572-1 · Cited by 138
RetractedWarburg, O. (1956) · Science · doi:10.1126/science.123.3191.309 · Cited by 13,425 · cited 1×
“Cancer cells characteristically display altered metabolism, producing ATP independent of the oxygen concentration (1), in a phenomenon known as theWarburg effect (2).”
BackgroundCycling of O-linked β-N-acetylglucosamine on nucleocytoplasmic proteins
Hart, G. W., Housley, M. P., & Slawson, C. (2007) · Nature · doi:10.1038/nature05815 · Cited by 1,418
The anaphase promoting complex/cyclosome: a machine designed to destroy
Peters, J.-M. (2006) · Nature Reviews Molecular Cell Biology · doi:10.1038/nrm1988 · Cited by 1,315
Cancer's Molecular Sweet Tooth and the Warburg Effect
Kim, J.-W., & Dang, C. V. (2006) · Cancer Research · doi:10.1158/0008-5472.can-06-1501 · Cited by 1,215
Carter, S. L., Eklund, A. C., Kohane, I. S., Harris, L. N., & Szallasi, Z. (2006) · Nature Genetics · doi:10.1038/ng1861 · Cited by 1,193
Oncogenic alterations of metabolism
Dang, C. V., & Semenza, G. L. (1999) · Trends in Biochemical Sciences · doi:10.1016/s0968-0004(98)01344-9 · Cited by 1,106
Marshall, S., Bacote, V, & Traxinger, R. R. (1991) · Journal of Biological Chemistry · doi:10.1016/s0021-9258(19)67706-9 · Cited by 1,047
Brick by brick: metabolism and tumor cell growth
DeBerardinis, R. J., Sayed, N., Ditsworth, D., & Thompson, C. B. (2008) · Current Opinion in Genetics & Development · doi:10.1016/j.gde.2008.02.003 · Cited by 1,018
Cited by
Glycosylation in cancer: mechanisms and clinical implications
Pinho, S. S., & Reis, C. A. (2015) · Nature Reviews Cancer · doi:10.1038/nrc3982 · Cited by 3,083
From Krebs to clinic: glutamine metabolism to cancer therapy
Altman, B. J., Stine, Z. E., & Dang, C. V. (2016) · Nature Reviews Cancer · doi:10.1038/nrc.2016.71 · Cited by 2,119
The hallmarks of cancer metabolism: still emerging
Pavlova, N. N., Zhu, J., & Thompson, C. B. (2022) · Cell Metabolism · doi:10.1016/j.cmet.2022.01.007 · Cited by 1,418
Phosphofructokinase 1 Glycosylation Regulates Cell Growth and Metabolism
Yi, W., Clark, P. M., Mason, D. E., Keenan, M. C., Hill, C., Goddard, W. A., Peters, E. C., Driggers, E. M., & Hsieh-Wilson, L. C. (2012) · Science · doi:10.1126/science.1222278 · Cited by 676
Sp1 and the ‘hallmarks of cancer’
Beishline, K., & Azizkhan‐Clifford, J. (2015) · The FEBS Journal · doi:10.1111/febs.13148 · Cited by 524
Hallmarks of glycosylation in cancer
Munkley, J., & Elliott, D. J. (2016) · Oncotarget · doi:10.18632/oncotarget.8155 · Cited by 521
Ferrer, C. M., Lynch, T. P., Sodi, V. L., Falcone, J. N., Schwab, L. P., Peacock, D. L., Vocadlo, D. J., Seagroves, T. N., & Reginato, M. J. (2014) · Molecular Cell · doi:10.1016/j.molcel.2014.04.026 · Cited by 442
Self-citationEnergy metabolism in health and diseases
Liu, H., Wang, S., Wang, J., Guo, X., Song, Y., Fu, K., Gao, Z., Liu, D., He, W., & Yang, L.-L. (2025) · Signal Transduction and Targeted Therapy · doi:10.1038/s41392-025-02141-x · Cited by 399
Fueling the fire: emerging role of the hexosamine biosynthetic pathway in cancer
Akella, N. M., Ciraku, L., & Reginato, M. J. (2019) · BMC Biology · doi:10.1186/s12915-019-0671-3 · Cited by 373
Self-citationAltered glycosylation in cancer: A promising target for biomarkers and therapeutics
Thomas, D., Rathinavel, A. K., & Radhakrishnan, P. (2021) · Biochimica et Biophysica Acta (BBA) - Reviews on Cancer · doi:10.1016/j.bbcan.2020.188464 · Cited by 372
Role of O-linked N-acetylglucosamine protein modification in cellular (patho)physiology
Chatham, J. C., Zhang, J., & Wende, A. R. (2021) · Physiological Reviews · doi:10.1152/physrev.00043.2019 · Cited by 352
Nutrient regulation of signaling and transcription
Hart, G. W. (2019) · Journal of Biological Chemistry · doi:10.1074/jbc.aw119.003226 · Cited by 345
Protein Glycosylation and Tumor Microenvironment Alterations Driving Cancer Hallmarks
Peixoto, A., Relvas-Santos, M., Azevedo, R., Santos, L. L., & Ferreira, J. A. (2019) · Frontiers in Oncology · doi:10.3389/fonc.2019.00380 · Cited by 334
O-GlcNAc Cycling: A Link Between Metabolism and Chronic Disease
Bond, M. R., & Hanover, J. A. (2013) · Annual Review of Nutrition · doi:10.1146/annurev-nutr-071812-161240 · Cited by 316
Dysregulated metabolism contributes to oncogenesis
Hirschey, M. D., DeBerardinis, R. J., Diehl, A. M. E., Drew, J. E., Frezza, C., Green, M. F., Jones, L. W., Ko, Y. H., Le, A., Lea, M. A., et al. (2015) · Seminars in Cancer Biology · doi:10.1016/j.semcancer.2015.10.002 · Cited by 305
A Small Molecule That Inhibits OGT Activity in Cells
Ortiz-Meoz, R. F., Jiang, J., Lazarus, M. B., Orman, M., Janetzko, J., Fan, C., Duveau, D. Y., Tan, Z.-W., Thomas, C. J., & Walker, S. (2015) · ACS Chemical Biology · doi:10.1021/acschembio.5b00004 · Cited by 294
Signaling pathways in cancer metabolism: mechanisms and therapeutic targets
You, M., Xie, Z., Zhang, N., Zhang, Y., Xiao, D., Liu, S., Zhuang, W., Li, L., & Tao, Y. (2023) · Signal Transduction and Targeted Therapy · doi:10.1038/s41392-023-01442-3 · Cited by 292
Itkonen, H. M., Minner, S., Guldvik, I. J., Sandmann, M. J., Tsourlakis, M. C., Berge, V., Svindland, A., Schlomm, T., & Mills, I. G. (2013) · Cancer Research · doi:10.1158/0008-5472.can-13-0549 · Cited by 292
O-GlcNAcylation in Cancer Biology: Linking Metabolism and Signaling
Ferrer, C. M., Sodi, V. L., & Reginato, M. J. (2016) · Journal of Molecular Biology · doi:10.1016/j.jmb.2016.05.028 · Cited by 267
Self-citationO-GlcNAcylation: A New Cancer Hallmark?
Fardini, Y., Dehennaut, V., Lefebvre, T., & Issad, T. (2013) · Frontiers in Endocrinology · doi:10.3389/fendo.2013.00099 · Cited by 263
Ma, Z., Vocadlo, D. J., & Vosseller, K. (2013) · Journal of Biological Chemistry · doi:10.1074/jbc.m113.470047 · Cited by 253
Self-citationGrant, G. D., Brooks, L., Zhang, X., Mahoney, J. M., Martyanov, V., Wood, T. A., Sherlock, G., Cheng, C., & Whitfield, M. L. (2013) · Molecular Biology of the Cell · doi:10.1091/mbc.e13-05-0264 · Cited by 179
Phillips, C. M., Zatarain, J. R., Nicholls, M. E., Porter, C., Widen, S. G., Thanki, K., Johnson, P., Jawad, M. U., Moyer, M. P., Randall, J. W., et al. (2017) · Cancer Research · doi:10.1158/0008-5472.can-16-3480 · Cited by 139
“Increased HBP flux and hyper-OGlcNAcylation of proteins have been observed in the same cancers exhibiting increased levels of CBS protein and activity including, prostate (32), lung and colorectal cancers (33).”
HINCUTs in cancer: Hypoxia-induced noncoding ultraconserved transcripts
Ferdin, J., Nishida, N., Wu, X., Nicoloso, M. S., Shah, M. Y., Devlin, C., Ling, H., Shimizu, M., Kumar, K., Cortez, M. A., et al. (2013) · Cell Death & Differentiation · doi:10.1038/cdd.2013.119 · Cited by 103
Self-citationGlutamine deprivation triggers NAGK-dependent hexosamine salvage
Campbell, S., Mesaros, C., Izzo, L., Affronti, H., Noji, M., Schaffer, B. E., Tsang, T., Sun, K., Trefely, S., Kruijning, S., et al. (2021) · eLife · doi:10.7554/elife.62644 · Cited by 58
Glycosylation in cancer: mechanisms, diagnostic markers, and therapeutic applications
Qusairy, Z., & Rada, M. (2025) · Molecular and Cellular Biochemistry · doi:10.1007/s11010-025-05303-1 · Cited by 16
O-GlcNAcylation of FOXK1 orchestrates the E2F pathway and promotes oncogenesis
Masclef, L., Ahmed, O., Iannantuono, N., Gagnon, J., Gushul-Leclaire, M., Boulay, K., Estavoyer, B., Echbicheb, M., Poy, M., Ali Boubacar, K., et al. (2024) · doi:10.1101/2024.03.01.582838 · Cited by 6
O-GlcNAcylation of FOXK1 co-opts BAP1 to orchestrate the E2F pathway and promotes oncogenesis
(2025) · doi:10.1038/s41467-025-61022-7 · Cited by 6
Metadata
- Authors
- Lynch, T. P., Ferrer, C. M., Jackson, S. R., Shahriari, K. S., Vosseller, K., & Reginato, M. J.
- Venue
- Journal of Biological Chemistry
- Publisher
- Elsevier BV
- Published
- 2012-03
- Volume
- 287
- Issue
- 14
- Pages
- 11070-11081
- ISSN
- 0021-9258 (ISSN-L)
- OpenAlex
- W2079492290
- Cited by
- 286
- References
- 38
- FWCI
- 9.18
- Type
- journal article
- Language
- en
- Open access
- hybrid
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.